Genetic characterization and clinical implications of human papillomavirus type 16 (HPV-16) variants from northeastern Argentina.

BADANO INÉS; TOTARO MARÍA ELINA; CULASSO ANDRÉS CARLOS ALBERTO; SANABRIA DAIANA JIMENA; SCHURR THEODORE G.; BALETTE ILEANA CRISTINA; ROISMAN ALEJANDRO; BASILETTI JORGE; PICCONI MARÍA ALEJANDRA; CAMPOS RODOLFO HÉCTOR; LIOTTA DOMINGO JAVIER

Infection, Genetics and Evolution

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2015 vol. 29 p. 103 - 109

1567-1348

BACKGROUND: Human papillomavirus type 16 (HPV 16) plays a central role in the development of cervical cancer. Worldwide studies indicate the existence of HPV-16 genetic variants that show a different geographic distribution and oncogenic potential. OBJECTIVE: Our goal was to describe the genetic variation of HPV 16 isolates identified in urban women with different grades of cervical lesions, living in Northeastern Argentina. STUDY DESIGN: We analyzed 116 HPV-16-positive cervical samples from patients attending health centers in Posadas city, Misiones (Argentina) during 2006 -13. The HPV 16 isolates were genetically characterized by PCR/sequencing of 364 bp within the Long Control Region, the resulting sequences classified into variants based on phylogenetics analysis (lineages A, B, C and D). The potential association between HPV 16 variants and lesion grade was evaluated by Odds Ratio (OR) test. A temporal framework for the origin of HPV 16 variants was assessed through coalescence analysis (BEAST v 1.7.5). RESULTS: The phylogenetic analysis of HPV 16 sequences showed that 92.1% of the samples clustered with lineage A, and 6.0% lineage D HPV 16 variants from lineage D were more frequently associated with high grade lesions and cancer (HSIL+) than lineage A variants at an OR of 13.8 (1.6 - 117.0). M CONCLUSION: Our results suggest that HPV 16 variants from lineage D may represent an additional risk factor for the development of cervical cancer in this population. This study provides new information about viral isolates present in Argentina that will contribute to the monitoring of HPV 16 infection in de vaccine era.